Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS (Unaudited)

v3.23.2
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 105 $ 2,937
Restricted cash 17 196
Receivables 9 36
Inventory 106
Prepaid expenses and other current assets 229 314
Discontinued operations - current assets 32 14
Current assets held for sale 106
Total current assets 498 3,603
Property and equipment, net 9 224
Other assets 48 48
Operating lease right-of-use assets, net 124 183
Noncurrent assets held for sale 133
Total assets 812 4,058
Current liabilities:    
Accounts payable 597 695
Accrued clinical trials expenses 3 5
Other accrued liabilities 676 1,483
Operating lease liability, current 128 122
Deferred grant revenue 16 196
Discontinued operations – current liabilities 190 129
Current liabilities held for sale 236
Total current liabilities 1,846 2,630
Operating lease liability, noncurrent 65
Total liabilities 1,846 2,695
Stockholders’ equity (deficit):    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 15,016,295 shares issued and outstanding at June 30, 2023 and December 31, 2022. 15 15
Additional paid-in capital 388,473 387,609
Accumulated deficit (389,522) (386,261)
Total stockholders’ equity (deficit) (1,034) 1,363
Total liabilities and stockholders’ equity (deficit) $ 812 $ 4,058